Chapter 2 Biological Response Modifier in Cancer Immunotherapy
Ronghua Liu,Feifei Luo,Xiaomin Liu,Luman Wang,Jiao Yang,Yuting Deng,Enyu Huang,Jiawen Qian,Zhou Lu,Xuechao Jiang,Dan Zhang,Y. Chu
2018-01-01
Abstract:Biological response modifiers (BRMs) emerge as a lay of new compounds or approaches used in improving cancer immunotherapy. Evidences highlight that cytokines, Toll-like receptor (TLR) signaling, and noncoding RNAs are of crucial roles in modulating antitumor immune response and cancer-related chronic inflammation, and BRMs based on them have been explored. In particular, besides some cytokines like IFN-α and IL-2, several Toll-like receptor (TLR) agonists like BCG, MPL, and imiquimod are also licensed to be used in patients with several malignancies nowadays, and the first artificial small noncoding RNA (microRNA) mimic, MXR34, has entered phase I clinical study against liver cancer, implying their potential application in cancer therapy. According to amounts of original data, this chapter will review the regulatory roles of TLR signaling, some noncoding RNAs, and several key cytokines in cancer and cancer-related immune response, as well as the clinical cases in cancer therapy based on them. R. Liu • L. Wang • J. Yang • Y. Deng • E. Huang • J. Qian • Z. Lu • X. Jiang • D. Zhang • Y. Chu (*) Department of Immunology, Key Laboratory of Medical Molecular Virology of MOE/MOH, School of Basic Medical Sciences, Fudan University, No.138, Yi Xue Yuan Rd., mail box 226, Shanghai 200032, People’s Republic of China Biotherapy Research Center, Fudan University, Shanghai 200032, China e-mail: yiweichu@fudan.edu.cn F. Luo Biotherapy Research Center, Fudan University, Shanghai 200032, China Department of Digestive Diseases of Huashan Hospital, Fudan University, Shanghai, China X. Liu Department of Immunology, Key Laboratory of Medical Molecular Virology of MOE/MOH, School of Basic Medical Sciences, Fudan University, No.138, Yi Xue Yuan Rd., mail box 226, Shanghai 200032, People’s Republic of China Department of Dermatology, Shenzhen Hospital, Peking University, Shenzhen, Guangdong 518036, China © Springer Science+Business Media Dordrecht 2016 S. Zhang (ed.), Progress in Cancer Immunotherapy, Advances in Experimental Medicine and Biology 909, DOI 10.1007/978-94-017-7555-7_2 69